What’s the ideal radiation therapy approach after breast-conserving surgery for early-stage breast cancer? A new study compares cost-effectiveness of accelerated partial breast and hypofractionated whole breast irradiation.
With his new, five-year, $1.8 million award, Dr. Gong hopes to improve PARPi therapy by better understanding the mechanisms of resistance.
Multigene panel testing should be considered for all African-American women with triple-negative breast cancer regardless of their age or cancer history.
A new option proves effective for patients with HER2+ early breast cancer with residual disease after neoadjuvant therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
In patients receiving radiation after mastectomy, 10-year outcomes show autologous breast reconstruction has fewer complications and reconstruction failures.
Immunotherapy hasn’t benefited breast cancer patients — yet. Breast medical oncologist Megan Kruse, MD, explains how that may be changing.
Researchers found no risk of cancer recurrence from autologous fat grating after breast reconstruction, but fat necrosis, a benign complication, can present as a lump.
Results of a multi-institutional phase 1b clinical trial show women with metastatic HER2+ breast cancer respond well to the combina-tion of trastuzumab emtansine and neratinib.
Dr. Shah’s team is preparing data for publication showing that cardiac doses at Cleveland Clinic are lower than the national standard by more than 50 percent.
Dr. Shah’s team is refining the use of intensity-modulated radiation therapy to deliver partial breast irradiation.